Combining and Sequencing Agents in CLL
William G. Wierda, M.D., Ph.D., medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses how to best combine and sequence therapies for patients with chronic lymphocytic leukemia (CLL).
William G. Wierda, M.D., Ph.D., medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses how to best combine and sequence therapies for patients with chronic lymphocytic leukemia (CLL).
In the past, patients were typically just treated with the single agents available at the time. In most community cancer centers, that was Imbruvica (ibrutinib). But now there are more agents approved and accessible in this space, so combining or sequencing them in a way that will lead to optimal outcomes is becoming an increasingly important field of research.
